Dylan Jovine’s “Cut And Paste” Stock Revealed

Dylan Jovine of Behind the Markets has a teaser he's been running for many years now.

In it, he claims that a new medical breakthrough "could cut and paste disease from your body."

Additionally, he claims there's the potential to collect over 46,000 returns from this one stock alone.

The good news is that there are enough clues in this teaser to figure out the name of the stock.

I reveal it below, along with information on the stock, so you can determine if it's worth buying.

Let's get started now!

Dylan Jovine's "Cut And Paste" FAQ's

If you watched Jovine's presentation on "cut and paste,"  I'm sure you have some questions.

Here are answers to any questions you might have about this company.

1) What is this stock teaser about?

Jovine is re-running a teaser he's been pitching about a "cut and paste" company that can remove disease from your body.

He claims this medical miracle can be found in this tiny vial:

Jovine claims this vial has the power to cure thousands of different genetic diseases.

Also, that this revolutionary medicine is better than traditonal pharmacueticals.

This is because it can cure many diseases instead of pharmaceuticals that focus on one disease at a time.

And that there's only 300 medicines to cure 6,000 genetic diseases.

Additionally, Jovine claims top drug companies have poured in over $1 billion combined to this mystery.

2) What medical technology is Dylan Jovine talking about?

The technology about which Dylan is talking is gene editing, or CRISPR.

With the use of the cutting-edge gene-editing technique CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), researchers may precisely change the genes within an organism.

It is based on a natural virus defense mechanism employed by bacteria, in which invader viruses' DNA is recognized and destroyed using RNA molecules.

A specially crafted RNA molecule is used by CRISPR technology to target a particular gene sequence located within the DNA of an organism.

The targeted DNA is subsequently sliced by an enzyme known as Cas9, enabling scientists to add, delete, or replace particular genetic material.

Through the use of this technology, it may be possible to treat genetic disorders, increase agricultural productivity, and even produce totally new species.

CRISPR's accuracy, effectiveness, and affordability have led to calls for it to be considered a revolutionary technique.

It has the potential to completely alter the disciplines of biotechnology, agriculture, and medicine.

However, there are ethical issues with CRISPR use as well, particularly when it comes to editing human embryonic genomes or generating novel species with unknowable ecological effects.

There are several controversies surrounding the use of CRISPR technology. Some of the main concerns include:

1. Off-target effects: CRISPR occasionally alters other regions of the genome without intent, which might have unforeseen results.
2. Ethical concerns: Editing human germline (eggs, sperm, or embryos) with CRISPR is highly debatable because it has the potential to produce "designer babies" with improved features. Concerns exist regarding the long-term implications of such genetic alterations for future generations.
3. Safety concerns: Some scientists are worried that CRISPR could result in unexpected mutations or other harmful health impacts.
4. Regulatory concerns: The quick development of CRISPR technology has surpassed the capacity of regulatory authorities, raising questions about the safety and moral consequences of its application.
5. Intellectual property disputes: The CRISPR technology's accessibility and influence may be constrained by ongoing legal conflicts about who has the right to use it.

So it's not like everyone is welcoming this new health trend with open arms.

I personally don't think I would ever take gene editing medicine.

Too creepy, in my opinion.

Recommended: The Best Places To Get Stock Picks

3) What is the stock Dylan Jovine is teasing?

Jovine has been pitching this stock for half a decade, so it's not a mystery, and all clues point to one company: Editas.

Editas Medicine creates and sells genome editing technologies. Cambridge, Massachusetts, serves as the company's corporate headquarters. It was established in 2013.

With the goal of treating diverse genetic illnesses, Editas is concentrating on developing CRISPR/Cas9 gene editing technology. They are working to create treatments for blood problems, cancer, and hereditary eye illnesses.

The goal of the company is to help the greatest number of patients by transforming the potential of genome editing research into a broad class of transformative genomic medicines.

Modern gene editing technology is used by Editas to precisely alter DNA, potentially curing or preventing a variety of genetic illnesses.

Is this company worth investing in? We'll answer that question next.

4) What are the pros and cons of investing in Editas?

I want to share some pros and cons you'll want to consider about this company.

The pros of investing in Editas Medicine may include:

1. Potential for high returns: Editas Medicine is a biotechnology business that has developed cutting-edge gene-editing technology that has the potential to completely change the way genetic illnesses are treated. Investors may see large returns if the company is successful in creating and marketing efficient gene medicines.
2. Strong partnerships: Editas has forged alliances with top pharmaceutical firms, notably Allergan, which may offer the business significant financial assistance and industry knowledge to help it promote its medications.
3. Experienced management team: Editas Medicine has a management team with extensive experience and a history of success in the biotech sector, which may give investors more confidence in the company's ability to carry out its business plan.

The cons of investing in Editas Medicine include:

1. Early-stage development: There is no assurance that Editas Medicine's medicines will be effective in clinical trials or get regulatory approval because the company's gene-editing technology is currently in its early phases of development.
2. High risk: Investing in Editas Medicine bears a high level of risk, similar to other biotech firms, because the company's medications depend heavily on variables outside of its control, such as regulatory approvals, market competition, and shifting industry trends.
3. Limited revenue: As a pre-revenue company, Editas Medicine does not currently make a sizable profit from its operations. This would make it challenging for the business to continue running in the short term, and it might need to raise more money to support the advancement of its gene-editing technology.

5) Is "Behind the Markets" worth it?

There's one last question to answer, and that's if Behind the Markets is worth it.

I wrote an entire review of this newsletter earlier this year, which you can read here.

I've actually spoken to Dylan Jovine before.

I personally think he's a decent enough guy and seems to want to help his subscribers make money.

However, the results of his newsletter haven't been great.

Overall, Behind the Markets hasn't beaten the market and has recently done very poorly.

I personally wouldn't buy the newsletter, even though it's pretty cheap.

Recommended: The Best Places To Get Stock Picks

Wrapping Things Up

So that's the end of my post on Dylan Jovine's "Cut and Paste" stock teaser presentation.

The company that he's pitching is Editas, which makes products related to gene editing.

I have my doubts about this technology and how influential it will be.

So I won't be investing in Editas or any other CRISPR stocks.

What about you?

Are you excited about these medical "breakthroughs" and planning on investing in Editas?

Let me know in the comments.